Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Summary of Leronlimab’s Path and Regulatory Conf

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 153798
(Total Views: 2326)
Posted On: 05/25/2025 8:05:47 AM
Posted By: biloxiblues
Re: biloxiblues #153525
Summary of Leronlimab’s Path and Regulatory Conflict
Under Dr. Nader Pourhassan’s leadership, CytoDyn’s drug leronlimab reached a major milestone by meeting its primary endpoint in a pivotal Phase 3 HIV trial. Amid the COVID-19 pandemic, several prominent physicians, including Dr. Seethamraju of Montefiore and Dr. Otto Yang of UCLA, independently sought Emergency Use Authorizations (EUAs) for critically ill COVID patients. Many of these patients experienced extraordinary recoveries—some from intubation or ECMO—prompting published findings in top-tier medical journals like the New England Journal of Medicine.

Despite real-world evidence and continuous safety affirmation from frontline physicians, the FDA limited CytoDyn’s COVID-19 trial to moderately ill patients—excluding the population where the drug had shown the most dramatic results. Still, in that critical group, leronlimab demonstrated a 33% mortality reduction.

While doctors and patients publicly attested to the drug’s life-saving potential, the DOJ pursued criminal charges against Dr. Pourhassan and Dr. Kazempour, CEOs of CytoDyn and its CRO. Both were acquitted of the central charge—conspiracy—but were convicted on lesser charges, despite rejecting plea deals that would have required them to admit to the very charge the jury dismissed.

During the trial, internal FDA emails—obtained via subpoena—unveiled a pattern of bias, hostility, and predetermined dismissal toward CytoDyn:

One official called CytoDyn “the mother f— company” and refused to even examine their data.

FDA Director Dr. Debra Birnkrant herself asked, “Why is this drug working?”—a striking question coming from a top regulator.

Internal communication contradicted the DOJ’s central claim that CytoDyn’s BLA was “unreviewable”; the FDA’s own BLA team lead stated otherwise.

Implications
This story raises urgent questions about regulatory integrity, institutional transparency, and the consequences of bureaucratic bias in the face of potential medical breakthroughs. It suggests a troubling disconnect between frontline medical evidence and the actions of those entrusted with public health oversight.

It also invites the public and policymakers to ask:
What if a life-saving drug was buried—not because it failed patients, but because it challenged a system unprepared for disruptive innovation?


(9)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us